Thomas Jefferson University Hopsital
Welcome,         Profile    Billing    Logout  
 9 Trials 
10 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lopez, Ana Maria
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
HARMONIA, NCT05207709 / 2021-002027-38: Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Recruiting
3
456
Europe, US
Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab
SOLTI Breast Cancer Research Group, Novartis, Alliance Foundation Trials, LLC.
Metastatic Breast Cancer
03/26
03/27
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Recruiting
3
1295
Canada, US
Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
05/33
05/33
ATREZZO, NCT04759248 / 2020-000245-13: Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Recruiting
2
55
Europe
Atezolizumab + Trastuzumab + Vinorelbine
SOLTI Breast Cancer Research Group, Roche Pharma AG
Breast Cancer
12/24
01/25
NRG-GY022, NCT03997370: Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Recruiting
1
350
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Iohexol, Omnipaque
NRG Oncology, National Cancer Institute (NCI)
Malignant Solid Neoplasm
02/27
02/28
NCT06219434: Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer

Recruiting
N/A
12
US
Mindfulness Relaxation, MBSR, Mindful Meditation, Mindfulness Meditation, Mindfulness-Based Stress Reduction, Functional Magnetic Resonance Imaging, fMRI, FUNCTIONAL MRI, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Questionnaire Administration
Thomas Jefferson University
Breast Carcinoma
10/25
10/25
NCT04086875: A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

Active, not recruiting
N/A
332
US
Focus Group, Text Message, SMS Text, SMS Text Message, Text, Best Practice, standard of care, standard therapy, Questionnaire Administration
Thomas Jefferson University, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive Tumor, Progesterone Receptor Positive Tumor, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
09/24
09/24
NCT04392050: A Community-Based Educational Intervention to Improve Colorectal Cancer Screening

Suspended
N/A
90
US
Interview, Focus Group, Questionnaire Administration
Thomas Jefferson University, National Cancer Institute (NCI)
Colorectal Carcinoma
09/25
09/25
SWOG-S1703, NCT03723928: S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Recruiting
N/A
739
US, RoW
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, STMDDM, Quality-of-Life Assessment, Quality of Life Assessment, Anxiety Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
12/30
12/36
NCT05062967: Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease

Not yet recruiting
N/A
3257
Europe
Maimónides Biomedical Research Institute of Córdoba
Hepatitis, Liver Diseases, Acute Hepatitis, Chronic Hepatitis, Liver Disease Chronic
10/24
12/24
Fisicaro, Marc
No trials found

Download Options